1st Eurofarma Synapsis comes to an end with 9 pilot projects and 50% of contracts signed with the company
Published in: December 4, 2018
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, November, 2018 – Eurofarma Synapsis, Eurofarma's startup acceleration program, developed in partnership with Endeavor, has just completed its first edition with very impressive results. Out of the 12 accelerated scale-ups, 9 have carried out pilot projects in the company, of which 50% have already concluded a service contract.
The project has brought a rich learning to the entire chain of innovation by accounting for more than 100 hours of mentoring for the scale-ups and almost 200 Eurofarma employees working on the selected projects.
Synapsis also had the active participation of Endeavor, a partner that supported Eurofarma in the selection process and highlighted 39 renowned mentors to monitor the development of companies. The startups selected provide robust innovative solutions for the entire healthcare chain, focusing on 5 macro-themes defined in the selection stage: stakeholder relationships, efficiency gains in key processes, sustainability, market intelligence and people management.
"The internal cultural impact was enormous, because the process required people to get out of the routine of their day-to-day work to think about how best to implement the solution that the startup brought into our reality," says Marco Billi, manager of M&A and Corporate Venture of Eurofarma.
Through the partnership with Endeavor, the goal of fostering entrepreneurship in the country and seeking innovation outside the company's borders has also been achieved. "Well-structured engagement initiatives between large corporations and innovative entrepreneurs in their industries generate positive impacts for participants in pursuit of business development, as is the case of Synapsis," said Luis Felipe Franco, Endeavor's Acceleration manager.
According to Maria Del Pilar Muñoz, vice president of Sustainability and New Businesses, Synapsis was a great opportunity for companies. "Eurofarma emerged from a dream and 45 years ago it was also a startup. We are happy with the feedback and engagement that Synapsis has received. One of our missions is to invest in Innovation and we believe that startups have an important role in bringing the national industry closer to open innovation", he concludes.
About Eurofarma Synapsis
The Eurofarma Synapsis platform has selected 12 scale-ups connected with the future and willing to be part of the transformation of the health sector in the areas: Relationship with Interest Groups, Efficiency Gains, Market Intelligence and People Management.
The selected companies have had mentoring with the Endeavor network and access to entrepreneurs at a similar growth stage. In addition, startups had the opportunity to leverage their business by engaging with information and trends in the healthcare industry - broadly audited, coaching in support areas such as Marketing, Sales and Logistics, and access to Eurofarma's network of relationships, which contemplates over 4 thousand suppliers, 1,500 active customers (B2B) and more than 600 thousand medical contacts per month, covering all specialties.
To learn more about accelerated scale-ups, click here
About Eurofarma Brazil
With 46 years of existence, the Eurofarma Group is the first Brazilian pharmaceutical multinational with 100% national capital, being recognized by the medical community and society for promoting access to health and quality of life with fair price, quality and innovation treatments.
Present in 20 countries, it operates in the Medical Prescription and Prescription-Free, Generic, Hospital, Bids, Oncology, Veterinary and Services to Third-party segments. In Brazil, the portfolio is represented by 335 brands in 844 presentations, including 28 medical specialties and 148 therapeutic classes.
For further Information, visit www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram: @eurofarma_br
Press information:
Eurofarma Laboratories
Stephanie Van Sebroeck - +55 11 5090-8600 ext. 8369 - stephanie@gaspar.com.br
Guilherme Gaspar – Phone +55 11 3065-3045 – guilherme@gaspar.com.br
The project has brought a rich learning to the entire chain of innovation by accounting for more than 100 hours of mentoring for the scale-ups and almost 200 Eurofarma employees working on the selected projects.
Synapsis also had the active participation of Endeavor, a partner that supported Eurofarma in the selection process and highlighted 39 renowned mentors to monitor the development of companies. The startups selected provide robust innovative solutions for the entire healthcare chain, focusing on 5 macro-themes defined in the selection stage: stakeholder relationships, efficiency gains in key processes, sustainability, market intelligence and people management.
"The internal cultural impact was enormous, because the process required people to get out of the routine of their day-to-day work to think about how best to implement the solution that the startup brought into our reality," says Marco Billi, manager of M&A and Corporate Venture of Eurofarma.
Through the partnership with Endeavor, the goal of fostering entrepreneurship in the country and seeking innovation outside the company's borders has also been achieved. "Well-structured engagement initiatives between large corporations and innovative entrepreneurs in their industries generate positive impacts for participants in pursuit of business development, as is the case of Synapsis," said Luis Felipe Franco, Endeavor's Acceleration manager.
According to Maria Del Pilar Muñoz, vice president of Sustainability and New Businesses, Synapsis was a great opportunity for companies. "Eurofarma emerged from a dream and 45 years ago it was also a startup. We are happy with the feedback and engagement that Synapsis has received. One of our missions is to invest in Innovation and we believe that startups have an important role in bringing the national industry closer to open innovation", he concludes.
About Eurofarma Synapsis
The Eurofarma Synapsis platform has selected 12 scale-ups connected with the future and willing to be part of the transformation of the health sector in the areas: Relationship with Interest Groups, Efficiency Gains, Market Intelligence and People Management.
The selected companies have had mentoring with the Endeavor network and access to entrepreneurs at a similar growth stage. In addition, startups had the opportunity to leverage their business by engaging with information and trends in the healthcare industry - broadly audited, coaching in support areas such as Marketing, Sales and Logistics, and access to Eurofarma's network of relationships, which contemplates over 4 thousand suppliers, 1,500 active customers (B2B) and more than 600 thousand medical contacts per month, covering all specialties.
To learn more about accelerated scale-ups, click here
About Eurofarma Brazil
With 46 years of existence, the Eurofarma Group is the first Brazilian pharmaceutical multinational with 100% national capital, being recognized by the medical community and society for promoting access to health and quality of life with fair price, quality and innovation treatments.
Present in 20 countries, it operates in the Medical Prescription and Prescription-Free, Generic, Hospital, Bids, Oncology, Veterinary and Services to Third-party segments. In Brazil, the portfolio is represented by 335 brands in 844 presentations, including 28 medical specialties and 148 therapeutic classes.
For further Information, visit www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram: @eurofarma_br
Press information:
Eurofarma Laboratories
Stephanie Van Sebroeck - +55 11 5090-8600 ext. 8369 - stephanie@gaspar.com.br
Guilherme Gaspar – Phone +55 11 3065-3045 – guilherme@gaspar.com.br